van der Merwe Jacques Q, Hollenberg Morley D, MacNaughton Wallace K
Inflammation Research Network, Department of Physiology, University of Calgary, Calgary, AB, Canada T2N 4N1.
Am J Physiol Gastrointest Liver Physiol. 2008 Feb;294(2):G441-51. doi: 10.1152/ajpgi.00303.2007. Epub 2007 Nov 21.
We examined the stimulus-secretion pathways whereby proteinase-activated receptor 2 (PAR-2) stimulates Cl(-) secretion in intestinal epithelial cells. SCBN and T84 epithelial monolayers grown on Snapwell supports and mounted in modified Ussing chambers were activated by the PAR-2-activating peptides SLIGRL-NH(2) and 2-furoyl-LIGRLO-NH(2). Short-circuit current (I(sc)) was used as a measure of net electrogenic ion transport. Basolateral, but not apical, application of SLIGRL-NH(2) or 2-furoyl-LIGRLO-NH(2) caused a concentration-dependent change in I(sc) that was significantly reduced in Cl(-)-free buffer and by the intracellular Ca(2+) blockers thapsigargin and BAPTA-AM, but not by the Ca(2+) channel blocker verapamil. Inhibitors of PKA (H-89) and CFTR (glibenclamide) also significantly reduced PAR-2-stimulated Cl(-) transport. PAR-2 activation was associated with increases in cAMP and intracellular Ca(2+). Immunoblot analysis revealed increases in phosphorylation of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase, Src, Pyk2, cRaf, and ERK1/2 in response to PAR-2 activation. Pretreatment with inhibitors of cyclooxygenases (indomethacin), tyrosine kinases (genistein), EGFR (PD-153035), MEK (PD-98059 or U-0126), and Src (PP1) inhibited SLIGRL-NH(2)-induced increases in I(sc). Inhibition of Src, but not matrix metalloproteinases, reduced EGFR phosphorylation. Reduced EGFR phosphorylation paralleled the reduction in PAR-2-stimulated I(sc). We conclude that activation of basolateral, but not apical, PAR-2 induces epithelial Cl(-) secretion via cAMP- and Ca(2+)-dependent mechanisms. The secretory effect involves EGFR transactivation by Src, leading to subsequent ERK1/2 activation and increased cyclooxygenase activity.
我们研究了蛋白酶激活受体2(PAR-2)刺激肠上皮细胞氯离子(Cl⁻)分泌的刺激-分泌途径。生长在Snapwell支持物上并安装在改良型尤斯灌流小室中的SCBN和T84上皮单层,通过PAR-2激活肽SLIGRL-NH₂和2-呋喃甲酰-LIGRLO-NH₂进行激活。短路电流(Isc)用作净电生性离子转运的指标。从基底外侧而非顶端施加SLIGRL-NH₂或2-呋喃甲酰-LIGRLO-NH₂会引起Isc的浓度依赖性变化,这种变化在无Cl⁻缓冲液中以及被细胞内Ca²⁺阻滞剂毒胡萝卜素和BAPTA-AM显著降低,但未被Ca²⁺通道阻滞剂维拉帕米降低。蛋白激酶A(PKA)抑制剂(H-89)和囊性纤维化跨膜传导调节因子(CFTR)抑制剂(格列本脲)也显著降低了PAR-2刺激的Cl⁻转运。PAR-2激活与环磷酸腺苷(cAMP)和细胞内Ca²⁺增加有关。免疫印迹分析显示,响应PAR-2激活,表皮生长因子(EGF)受体(EGFR)酪氨酸激酶、Src、Pyk2、cRaf和细胞外信号调节激酶1/2(ERK1/2)的磷酸化增加。用环氧化酶抑制剂(吲哚美辛)、酪氨酸激酶抑制剂(染料木黄酮)、EGFR抑制剂(PD-153035)、丝裂原活化蛋白激酶/细胞外信号调节激酶(MEK)抑制剂(PD-98059或U-0126)和Src抑制剂(PP1)预处理可抑制SLIGRL-NH₂诱导的Isc增加。抑制Src而非基质金属蛋白酶可降低EGFR磷酸化。EGFR磷酸化的降低与PAR-2刺激的Isc降低平行。我们得出结论,激活基底外侧而非顶端的PAR-2通过cAMP和Ca²⁺依赖性机制诱导上皮Cl⁻分泌。分泌效应涉及Src介导的EGFR反式激活,导致随后的ERK1/2激活和环氧化酶活性增加。